Integral Diagnostics Limited provided earnings guidance for the first half and full year 2018. The unaudited first half 2018 normalized results show an improvement in operating margin and all other key financial performance metrics which is expected to continue. The company now expects achievement of full year 2018 normalized NPAT growth of around 20% (before takeover response costs and transaction costs) compared to $15.1 million a year ago. Capital expenditure for the full year is forecast at $17 million compared to $13.4 million a year ago. Growth capital expenditure remains at $8 million and maintenance at $9 million.